Supported by a grant from the Gastrostart Fund of the Netherlands Society of Gastroenterology (Project 2005-14).
Risk of malignant lymphoma in patients with inflammatory bowel diseases: A Dutch nationwide study†
Article first published online: 22 DEC 2010
Copyright © 2010 Crohn's & Colitis Foundation of America, Inc.
Inflammatory Bowel Diseases
Volume 17, Issue 9, pages 1837–1845, September 2011
How to Cite
Vos, A.C.W., Bakkal, N., Minnee, R.C., Casparie, M.K., de Jong, D.J., Dijkstra, G., Stokkers, P., van Bodegraven, A.A., Pierik, M., van der Woude, C.J., Oldenburg, B., Hommes, D.W. and for the Initiative on Crohn's and Colitis (ICC) (2011), Risk of malignant lymphoma in patients with inflammatory bowel diseases: A Dutch nationwide study. Inflamm Bowel Dis, 17: 1837–1845. doi: 10.1002/ibd.21582
- Issue published online: 9 AUG 2011
- Article first published online: 22 DEC 2010
- Manuscript Accepted: 20 OCT 2010
- Manuscript Received: 18 AUG 2010
- Netherlands Society of Gastroenterology
- malignant lymphoma;
- Crohn's disease;
- ulcerative colitis;
- inflammatory bowel diseases;
- Epstein-Barr virus
Immune suppressant medications such as thiopurines and anti-tumor necrosis factor agents are important for maintaining disease control in most patients with inflammatory bowel diseases (IBDs); however, their use has been associated with the development of malignant lymphoma. The purpose of this Dutch nationwide study was to estimate the relative risk of malignant lymphoma in IBD patients.
IBD patients who developed a lymphoma between 1997 and 2004 were identified using the Dutch National Database of PALGA. Data from confirmed cases were collected from individual hospitals, including data on Epstein–Barr virus (EBV). The age-adjusted 8-year incidence of malignant lymphoma in the Netherlands was retrieved from the Central Bureau of Statistics.
Forty-two hospitals were visited and 285 matches evaluated in the total cohort of 17,834 IBD patients. Forty-four lymphomas were observed, resulting in a relative risk of 1.27 (95% confidence interval [CI]: 0.92–1.68). Only 19 of 44 patients (43%) were exposed to azathioprine/6-mercaptopurine (AZA/6-MP). Remarkably, 92% of patients (11/12) with EBV-positive lymphoma used AZA/6-MP, in contrast to only 19% patients (4/21) with EBV-negative lymphoma, suggesting a strong relation between EBV-positive lymphoma and thiopurine use.
This nationwide study does not suggest a significant overall increased risk for lymphoma in IBD patients. A distinct correlation between EBV-positive lymphoma and AZA/6-MP use was observed. (Inflamm Bowel Dis 2011;)